Trial Profile
A Phase I Trial of the Safety and Immunogenicity of a Multi-epitope HER-2/Neu Peptide Vaccine in Subjects Previously Treated for HER-2 Positive Breast Cancer
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 07 Nov 2021
Price :
$35
*
At a glance
- Drugs TPIV 100 (Primary)
- Indications Advanced breast cancer; Early breast cancer; HER2 positive breast cancer; Male breast cancer
- Focus Adverse reactions; Pharmacodynamics
- Sponsors TapImmune
- 06 Sep 2016 According to TapImmune media release, the company has requested a pre-Investigational New Drug (IND) meeting with the FDA and submitted questions to the FDA related to opening the IND, and a response from the FDA is expected in September and it anticipates having an open IND by year-end pending comments from FDA.
- 07 Dec 2015 According to a TapImmune Inc. media release, data will be presented at the 2015 San Antonio Breast Cancer Symposium.
- 23 Jun 2015 Status changed from active, no longer recruiting to completed according to a TapImmune media release.